Onconova Therapeutics (NASDAQ:ONTX) will release its earnings data before the market opens on Tuesday, March 26th. Analysts expect Onconova Therapeutics to post earnings of ($1.09) per share for the quarter.
ONTX stock opened at $4.26 on Friday. Onconova Therapeutics has a 52-week low of $1.69 and a 52-week high of $15.30. The company has a market cap of $24.15 million, a PE ratio of -0.11 and a beta of 2.86.
A number of research firms have recently issued reports on ONTX. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Onconova Therapeutics in a report on Friday, February 8th. ValuEngine lowered shares of Onconova Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 2nd. Zacks Investment Research lowered shares of Onconova Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 16th. Finally, Maxim Group set a $16.00 price target on shares of Onconova Therapeutics and gave the company a “buy” rating in a report on Monday, December 3rd.
ILLEGAL ACTIVITY NOTICE: “Onconova Therapeutics (ONTX) Set to Announce Quarterly Earnings on Tuesday” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://dakotafinancialnews.com/2019/03/24/onconova-therapeutics-ontx-set-to-announce-quarterly-earnings-on-tuesday.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.